南非夸祖鲁-纳塔尔省HIV疫苗与单克隆抗体试验筛查参与者的特征及参与动机
本研究对南非夸祖鲁-纳塔尔省四个站点五项HIV疫苗与单克隆抗体试验的筛查数据进行二次分析,共纳入1934名筛查参与者(79.2%为女性),其中1034人入组、900人被筛除或拒绝。筛查参与者以黑人、异性恋、顺性别男女为主,43.9%未完成中学教育,10.8%为HIV感染者;避免HIV风险是参与试验的主要动机,其次为帮助社区或寻找疫苗等利他原因。
要点
- 筛查参与者中女性占79.2%,43.9%未完成中学教育,10.8%为HIV感染者。
- 避免HIV风险是参与试验的主要动机,其次为帮助社区或寻找疫苗等利他原因。
- 作者认为当前招募方式吸引寻求降低HIV风险并支持社区的异性恋参与者。
核心结论
- 当前试验招募方式吸引寻求降低HIV风险并支持社区的异性恋参与者,数据提示持续HIV预防工作的必要性及潜在接受度。
研究设计与样本
- 对南非夸祖鲁-纳塔尔省四个站点五项HIV疫苗与单克隆抗体试验的筛查数据进行二次分析,共1934名筛查参与者(1034人入组,900人被筛除或拒绝)。
- 回顾性分析病例报告表与筛查问卷中的人口学、行为、动机及健康相关数据,采用描述性统计、卡方检验和单因素方差分析,使用R 3.5.2版本进行分析。
主要发现
- 筛查参与者中79.2%为女性,43.9%未完成中学/高中,10.8%为HIV感染者。
- 筛查参与者主要自我认同为黑人、异性恋、顺性别男女,许多人报告自身及伴侣存在HIV风险行为。
- 避免HIV风险是参与临床试验的主要动机,其次为帮助社区或帮助寻找疫苗等利他原因。
临床怎么用
- 作者认为站点可考虑更灵活的工作时间以方便在职参与者,并设法将参与者与教育支持及提升教育水平的机会联系起来。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: HIV is one of the greatest public health challenges in South Africa. Potential HIV vaccines and antibodies are thought to be cost-effective biomedical HIV prevention methods and are currently under investigation in phase I, II, and III trials. Consequently, current and future clinical trials need to ensure sufficient recruitment and retention. To achieve this goal, clinical trial staff need to understand the socio-demographic and behavioural characteristics of people volunteering to screen for these trials and their reasons for volunteering. METHODS: We conducted a secondary analysis of participant screening data across five vaccine and monoclonal antibody trials at four sites in KwaZulu-Natal, South Africa. Our study reviewed the demographic, behavioural, motivational, and health-related data from the case report forms and screening questionnaires. Descriptive statistics, chi-squared, and one-way ANOVA tests were used to analyse participants' characteristics and motivation to participate in HIV vaccine and monoclonal antibody trials. Analyses were conducted using R version 3.5.2. RESULTS: Screening data from 1934 participants, including 79.2% of women, were obtained across all five trials (1034 enrolled, 900 screened out/declined). Screened participants predominately self-identified as black, heterosexual, cisgender women or men, many with lower educational backgrounds (43.9% did not complete secondary/high school), and several self-reported HIV-risk behaviours among themselves and their partners. 10.8% of the screened participants were living with HIV. Avoiding HIV risk was the main motivation to participate in clinical trials, followed by altruistic reasons such as a desire to help the community or helping to find a vaccine. DISCUSSION: The current recruitment approach of these trials attracts heterosexual participants who seek to reduce HIV risk and support their community. Hence, the data suggest the need for and potential acceptance of continued ongoing HIV prevention efforts. Current trials attract participants with lower educational levels, which may be driven by the site locations, current community mobilisation strategies and research site opening hours. The sites could consider more flexible working hours to accommodate working participants and find ways to connect participants to educational support and opportunities to upgrade education levels for the current clientele. TRIAL REGISTRATION: HVTN 100: A Safety and Immune Response Study of 2 Experimental HIV Vaccines, NCT02404311 . Registered on March 17, 2015. HVTN 111: Safety and Immune Response to a Clade C DNA HIV Vaccine, NCT02997969. Registered on December 16, 2016. HVTN 108: Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults, NCT02915016. Registered on September 22, 2016. HVTN 702: Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa, NCT02968849. Registered on November 1, 2016. HVTN 703/HPTN 081: Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection in Women, NCT02568215 . Registered on October 1, 2015.
引用
- Hanass-Hancock J, Carpenter B, Reddy T, et al. Participants' characteristics and motivations to screen for HIV vaccine and monoclonal antibody trials in KwaZulu-Natal, South Africa. Trials. 2021. PMID: 34895272. doi:10.1186/s13063-021-05792-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。